Skip to main content

Deanna L. Kelly, PharmD, BCPP

Academic Title:

Professor

Primary Appointment:

Psychiatry

Additional Title:

Professor of Psychiatry Affiliate Professor of Pharmacy Practice and Science

Location:

MPRC, Treatment Research Program

Phone (Primary):

410-402-6861

Phone (Secondary):

410-402-6860

Fax:

410-402-6880

Education and Training

Education

1995: B.S., Pharmacy, Duquesne University, Mylan School of Pharmacy (Magna Cum Laude)

1996: Pharm.D., Duquesne University, Mylan School of Pharmacy

Post Graduate Education and Training

1996 - 1997: Psychiatric Pharmacy Practice Residency, University of Maryland Baltimore

Certifications

1998-present: Board Certified in Psychiatric Pharmacy Practice

Biosketch

Deanna L. Kelly, Pharm.D., BCPP is Professor of Psychiatry at University of Maryland Baltimore School of Medicine and Affiliate Professor in the School of Pharmacy. She is currently Director and Chief of the Treatment Research Program at the Maryland Psychiatric Research Center (MPRC). Dr. Kelly received her Bachelor of Science and Doctorate in Pharmacy at DuquesneUniversity in Pittsburgh, PA. She completed residency training in psychiatric pharmacy practice at the University of Maryland in 1997 and became board certified in psychiatric pharmacy practice in 1998.

Dr. Kelly has led and been involved in numerous clinical trials in schizophrenia and has been active in psychopharmacology research for the past 20 years. She has been continuously funded by NIMH, NIDA, and private foundations such as the Stanley Medical Research Institute and the Maryland Innovation Initiative for over 17 years.  She has specific interest in studying new treatments, women’s mental health, clozapine and immune function and inflammation.

Dr. Kelly has coauthored and authored 18 books and book chapters, published 171 peer-reviewed articles, presented over 140 posters and has given over 140 invited lectures. She has coauthored three editions of the book entitled “Pharmacologic Treatment of Schizophrenia.” She also authors the Schizophrenia chapter for “Pharmacotherapy, Principles and Practice.” Among many other activities she reviews for over 30 psychiatry journals and serves as a founding and current Associate Editor for Clinical Schizophrenia and Related Psychoses. Dr Kelly chairs the Junior Faculty Mentoring Committee at MPRC, and serves as Vice Chair of the State of Maryland Department of Health and Mental Hygiene Institutional Review Board.

She is the current President for the College of Psychiatric & Neurologic Pharmacists and recipient of the 2017 Maltz Prize for Innovative and Promising Schizophrenia Research from the Brain and Behavior Research Foundation

Research/Clinical Keywords

schizophrenia research, antipsychotic medication, women, gluten, clinical trials

Highlighted Publications

Kelly, DL, Sullivan KM, McEvoy JP, McMahon RP, Wehring HJ, Liu F, Warfel D, Vyas G, Richardson CM, Fischer BA, Keller WR, Koola MM, Feldman, SM, Russ JC, Keefe RS, Osing J, Hubzin L, August A, Walker TM, Buchanan RW.  Adjunctive Minocycline in clozapine treated schizophrenia patients with persistent symptoms. J Clin Psychopharmacol. 2015 Aug;35(4):374-81. doi: 10.1097/JCP.0000000000000345. PMID: 26082974

Richardson CM*, Davis EA,* Vyas GR, DiPaula BA, McMahon RP, Kelly DL. Evaluation of the safety of clozapine use in patients with benign neutropenia.  J Clin Psych 2016;77(11):e1454-e1459.  PMID: 27736047.

Cihakova D, Eaton WW, Talor MV, Harkus UH, Demyanovich H, Rodriguez K, Feldman S, Kelly DL.   Gliadin-related antibodies in schizophrenia. Schizophrenia Research, 2017, epub ahead of print  PMID: 28886891

Kelly DL, Freudenreich O, Sayer MA, Love RC. Addressing barriers to clozapine underutilization: a national effort. Psychiatr Serv 2017, epub ahead of print. PMID  29032704.

Kelly DL, Demyanovich HK, Eaton W, Cascella N, Jackson J, Fasano A, Carpenter WT. Antigliadin antibodies (AGA IgG) related to peripheral inflammation in schizophrenia. Brain Behav Immun 2017, epub ahead of print. PMID  29074356

Additional Publication Citations

Peer Reviewed Book Chapters

  1. Conley RR, Kelly DL. Pharmacologic treatment of schizophrenia. Professional Communications, Inc. First Edition, Caddo, OK 2000.
  2. Conley RR, Kelly DL. Pharmacologic treatment of schizophrenia.  Professional Communications, Inc. Second Edition, Caddo, OK 2003.
  3. Conley RR, Kelly DL. Pharmacologic treatment of schizophrenia.  Professional Communications, Inc. Third Edition, Caddo, OK, 2007.
  4. Conley RR, Kelly DL. The long-term efficacy, effectiveness and safety of second-generation antipsychotic drugs. In: Atypical antipsychotics: from bench to bedside. Editors: Csernansky JG, Lauriello J.  Marcel Dekker 2004.
  5. Conley RR, Kelly DL. Schizophrenia.  In Conn’s Current Therapy 2005.  Editors:  Rakel R and Bope E. Philadelphia, PA: W.B. Saunders, Philadelphia 2005, pp. 1280-1284.
  6. Conley RR, Kelly DL. Schizophrenia. In Conn’s Current Therapy 2006. Editors: Rakel R and Bope E. Philadelphia, PA:  W. B. Saunders, Philadelphia 2006, 1370-1374.
  7. Boggs D, Kelly DL, Conley RR. Antipsychotic Therapeutics (Efficacy and Side Effects). In The Year in SchizophreniaVolumeI. Editors: Thaker G, Carpenter WT., Clinical Publishing, Oxford, UK.  2007,209-231.
  8. Kelly DL, Weiner E. Schizophrenia, in Pharmacotherapy Principles and Practice, Chisholm-Burns M, Wells BG, Schwinghammer TL, et al (eds), McGraw-Hill, New York, New York, 2008.
  9. Kelly DL, Boggs DL, Conley RR. Reaching for wellness in schizophrenia:  A Complex Disease Necessitating Complex Care. Psychiatric Clinics of North America, Buckley PF, Messias EL (eds), Saunders, Philadelphia, PA 2007;30:453-479.
  10. Boggs D, Kelly DL. Antipsychotic Therapeutics. In The Year in Schizophrenia Volume II. Editors: Thaker G, Carpenter WT., Clinical Publishing, Oxford, UK.  2008.
  11. Wehring HJ, Kelly DL. Sexual Dysfunction in Schizophrenia. In: Medical Illness in Schizophrenia, second edition 2009. Eds Meyer JM, Nasrallah HA. American Psychiatric Publishing, Inc.
  12. Kelly DL, Weiner E, Wehring H. Schizophrenia, in Pharmacotherapy Principles and Practice, second edition. Chisholm-Burns M, Wells BG, Schwinghammer TL, et al (eds), McGraw-Hill, New York, New York, 2010.
  13. Perez G, Dixon L, Kelly DL. Evidence Based Medicine. In: Levin BL, Becker MA (Eds.). A Public Health Perspective of Women's Mental Health. New York: Springer, 2010.
  14. Kelly DL, Buchanan RW. Clozapine: It’s Current Status In and Beyond Treatment Resistant Schizophrenia. In: Therapeutic Strategies in Schizophrenia. 2010. Eds., P McKenna, A. Mortimer. Clinical Publishing Limited.
  15. Wehring HJ, Kelly DL. Schizophrenia. In; Pharmacotherapy Principles & Practice Study Guide:  A Cased Based Care Plan Approach, First Edition.  Michael D. Katz, Kathryn R. Matthias, and Marie A. Chisholm-Burns, Editors. The McGraw-Hill Companies, Inc. 2010.
  16. Kelly DL, Weiner E, Wehring H. Schizophrenia, in Pharmacotherapy Principles and Practice, third edition, Chrisholm, Burns M, Wells BG, Schwinghammer TL, et al (eds), McGraw-Hill, New York, New York, 2012
  17. Kelly DL, Weiner E, Wehring H. Schizophrenia, in Pharmacotherapy Principles and Practice, third edition, Chrisholm, Burns M, Wells BG, Schwinghammer TL, et al (eds), McGraw-Hill, New York, New York, 2014
  18. Kelly DL, Weiner E, Wehring H. Schizophrenia, in Pharmacotherapy Principles and Practice, fourth edition, Chrisholm, Burns M, Wells BG, Schwinghammer TL, et al (eds), McGraw-Hill, New York, New York, 2016.

Peer-reviewed journal articles

  1. Moore DB, Kelly DL, Sherr JD, Love RC, Conley RR. Rehospitalization rates of depot antipsychotics and pharmacoeconomic implications: comparison with risperidone. American Journal of Health-Systems Pharmacy. 1998;55(4):17-19. PMID: 987268.
  2. Sherr JD, Kelly DL.  Substitution of immediate release valproic acid for divalproex sodium for adult psychiatric inpatients.  Psychiatric Services. 1998;49:1355-57. PMID: 9779912.
  3. Conley, RR, Kelly DL, Gale E. Olanzapine response in therapy-refractory schizophrenia with substance abuse.  Schizophrenia Research. 1998;33:95-101. PMID: 9783349.
  4. Kelly DL, Conley RR, Love RC, Horn DS, Ushchak CM.  Weight gain in adolescents treated with risperidone and conventional antipsychotics. The Journal of the Child and Adolescent Psychopharmacology. 1998;8:151-159. PMID: 9853689.
  5. Kelly DL, Conley RR, Tamminga CA.   Differential olanzapine plasma concentrations by sex in a fixed dose study. Schizophrenia Research. 1999;40(2):101-4. PMID: 10593449.
  6. Conley RR, Love RC, Kelly DL, Bartko JJ. Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. American Journal of Psychiatry. 1999;156:863-868. PMID:10360124.
  7. Conley RR, Tamminga CA, Kelly DL, Richardson C. Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response.  Biological Psychiatry. 1999; 46;73-77. PMID:10394475.
  8. Love RC, Conley RR, Kelly DL, Bartko JJ. A dose-outcome analysis of risperidone. J Clin Psychiatry. 1999;60:771-775. PMID: 10584767.
  9. Kelly DL, Love RC. Ziprasidone and the QTc: pharmacokinetic and pharmacodynamic considerations. Psychopharmacology Bulletin. 2001;35:66-79. PMID: 12397857.
  10. Richardson C, Kelly DL, Conley RR. Biperiden for excessive sweating associated with clozapine use. Am J Psychiatry. 2001;158:1329-30. PMID: 11481174.
  11. Conley RC, Kelly DL. Management of treatment-resistant schizophrenia. Biological Psychiatry. 2001;50:898-911.PMID: 11743944.
  12. Kelly DL, Nelson MW, Love RC, Yu Y, Conley RR. Comparison of discharge rates and drug costs for patients with schizophrenia treated with risperidone or olanzapine.  Psychiatric Services. 2001;52:676-8. PMID: 11331805.
  13. Conley RR, Kelly DL. Current status of antipsychotic treatment. Current Drug Targets - CNS and Neurological Disorders. 2002;1:123-128. PMID:12769630.
  14. Kreyenbuhl J, Kelly DL, Conley RR.  Circumstances of suicide among patients with schizophrenia. Schizophrenia Research. 2002;58(2-3):253-6. PMID: 12409166.
  15. McMahon RP, Kelly DL Kreyenbuhl J, Kirkpatrick B, Love RC, Conley RR. Novel factor-based symptom scores in treatment-resistant schizophrenia: implications for clinical trials. Neuropsychopharmacology. 2002;537-545. PMID: 11927178.
  16. Kelly DL, Conley RR, Richardson CM, TammingaCA, Carpenter WT Jr. Adverse Effects and Laboratory Parameters of High-Dose Olanzapine vs. Clozapine in Treatment-Resistant Schizophrenia. Annals of Clin Psychiatry. 2003;15:181-6. PMID: 14971863.
  17. Kelly DL, Kreyenbuhl J, Love RC, Van-Duong Q, Conley RR. Six-month review of weight and metabolic parameters in patients on clozapine, risperidone, olanzapine and quetiapine. Journal of Clinical Psychiatry. 2003;64:1133-4. PMID: 14628994.
  18. Kelly DL, Gale EA, Yu Y, Conley RR. Clozapine treatment in patients with prior substance abuse. Canadian Journal of Psychiatry. 2003;48(2):111-4.
  19. Kelly DL, Conley RR. Evaluating sexual function in patients with treatment-resistant schizophrenia.  Schizophrenia Research. 2003;63(1-2):195-6. PMID: 12892874.
  20. Wehring H, Kelly DL, Love RC, Conley RR. Deaths from diabetic ketoacidosis after long-term clozapine treatment. Am J Psychiatry. 2003;160:2241-2242. PMID:14638600.
  21. Lambert TJR, Cock N, Alcock S, Kelly DL, Conley RR. Measurement of antipsychotic-induced side effects: Support for the validity of a self-report (LUNSERS) vs. structured interview (UKU) approach to measurement. Human Psychopharmacology. 2003;18(5):405-41. PMID:12858330.
  22. Nelson M, Reynolds R, Kelly DL, Conley RR. Adjunctive quetiapine decreases symptoms of tardive dyskinesia in a patient taking risperidone: case report. Clinical Neuropharmacology. 2003;26:297-8. PMID: 14646608.
  23. Conley RR, Kelly DL, Love RC, McMahon RP. Rehospitalization risk with second-generation and depot antipsychotics. Annals of Clinical Psychiatry. 2003. 15:23-31. PMID:12839430.
  24. Conley RR, Kelly DL, Richardson CM, TammingaCA, Carpenter WT Jr.  The Efficacy of High Dose Olanzapine vs. Clozapine in Treatment-Resistant Schizophrenia: A Double-Blind Crossover Study.  J Clin Psychopharmacology. 2003;23:668-671. PMID: 14624201.
  25. Lambert TJ, Brenan A, Castle DJ, Kelly DL, Conley RR. Perception of depot antipsychotics by mental health professionals. J Psychiatric Practice. 2003;9(3):252-260. PMID: 15985940.
  26. Love RC, Kelly DL. Olanzapine and risperidone. American Journal of Health-Systems Pharmacy. 2003;60:487-88. PMID: 12635459.
  27. Shim J-C, Kelly DL, Kim Y-H, Yoon Y-R, Park JH, Shin J-G, Conley RR. Fluoxetine augmentation of haloperidol in chronic schizophrenia. J Clin Psychopharmacology. 2003; 520-2. PMID:14520132
  28. Lambert, TJ, Kelly DL, Alcock S, Conley RR. Psychotropic prescribing for acute inpatient admissions in patients with severe psychosis. J Clin Psychopharmacology. 2004;24:91-3. PMID: 14709954
  29. Kelly DL, Conley RR. Sexuality and schizophrenia: a review. Schizophrenia Bulletin: 2004;30:767-779. PMID:15954189
  30. Kelly DL, Shim J-C, Feldman SM, Yu Y, Conley RR. Lifetime Psychiatric Symptoms in Persons with Schizophrenia Who Died by Suicide Compared to Other Means of Death. J of Psychiatric Research. 2004;38:531-36. PMID:15380404
  31. Kelly DL, Love RC, Mackowick M, Conley RR. Atypical Antipsychotic Use in a StateHospital Inpatient Adolescent Population, Journal of Child and Adolesc Psychopharmacology. 2004; 14(1):75-85. PMID:15142394
  32. Conley RR, Kelly DL, Beason-Held, Holcomb H, Richardson C, Tamminga CA, Carpenter WT. The effects of clozapine and high dose olanzapine on brain function in treatment-resistant schizophrenia: a case study. Journal of Psychopharmacology. 2004;18:429-31. PMID:15358989
  33. Kim YH,Shim J-C, Kelly DL, Lee J-G, Seo Y-S, Conley RR. Cortisol Response to Buspirone in Extended Abstinent Alcoholics. Alcohol and Alcoholism. 2004;39(4):287-289. PMID:15208158
  34. Conley RR, Shim JC, Kelly DL, Yu Y, Feldman S, McMahon RP. Cardiovascular disease in Relation to Weight in deceased persons with schizophrenia. Comprehensive Psychiatry. 2005;46:460-7. PMID:16275214
  35. Conley RR, Kelly DL.  Review of Current Drug Targets and Pharmacology of Antipsychotic Treatment. Medicinal Chemistry Reviews- Online. 2005;2(3):177-182.
  36. Jung DU, Seo YS, Park JH, Jeong CY, Conley RR, Kelly DL, Shim JC. The prevalence of hyperprolactinemia after long-term haloperidol use in patients with chronic schizophrenia. J Clin Psychopharmacol 2005;25:613-615, PMID:16282852.
  37. Kelly DL. The Schizophrenic Patient: The Reproductive Years and Beyond The Female Patient, OB-GYN edition, 2005;30(8):22-31.
  38. Conley RR, Kelly DL. Second-generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effects. Israel Journal of Psychiatr and Related Sciences. 2005;42(1):51-60. PMID:16134407
  39. Conley RR, Kelly DL, Nelson M, Richardson CM, Feldman S, Reynolds R, Steiner P, Yu Y, Khan I, McMullen R, Gale E, Mackowick M, Love R. Risperidone and quetiapine vs. fluphenazine in treatment-resistant schizophrenia. Clinical Neuropharmacology. 2005;28(4):163-8. PMID:16062094
  40. Kelly DL, Carpenter WT, Conley RR. First Episode Schizophrenia: A Focus on Pharmacologic Treatment and Safety Considerations. Drugs. 2005; 65:1113-38. PMID:15907146
  41. Conley RR, Kelly DL, Lambert TJ, Love RC. A comparison of clozapine use in Maryland and in Victoria, Australia. Psychiatric Services. 2005;56:320-3. PMID:15746507
  42. Kelly DL, Conley RR. Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone or fluphenazine. Journal of Clinical Psychiatry. 2005;66:80-84. PMID:15669892
  43. Shim J-C Kim Y-H, Kelly DL, Lee J-G, Conley RR. Tardive dyskinesia predicts prolactin response to buspirone challenge in people with schizophrenia.  Journal of Neuropsychiatry and Clinical Neurosciences. 2005;17:221-6. PMID:15939977
  44. Kelly DL. Treatment Considerations in Women with Schizophrenia. Journal of Women’s Health. 2006;15:1132-40.  PMID:17199454
  45. Kelly DL, Kreyenbuhl J, Dixon L, Love RC, Medoff D, Conley RR. Clozapine Underutilization and Discontinuation in African-Americans Due to Leucopenia. Schizophrenia Bulletin. 2007;33(5):1221-4. PMID:17170061 
  46. Kelly DL, Dixon L, Kreyenbuhl J, Lehman AF, Love RC, Medoff D, Brown C, Conley RR. Clozapine Utilization and Outcomes by Race in a Public Mental Health System: 1994-2000. J Clin Psychiatry. 2006;67:1404-11. PMID:17017827
  47. Jung D-O, Conley RR, Kelly DL, Kim D_W, Yoon S-H, Jang J-H, Shin J-G, Shim J-C. The Prevalence of Bone Mineral Density Loss in the Korean Patients with Chronic Schizophrenia. J Clin Psychiatry. 2006;67:1391-96. PMID:17017825
  48. Kelly DL, Richardson CM, Yu Yang, Conley RR. Plasma Concentrations of High Dose Olanzapine in a Double Blind Crossover Study. Human Psychopharmacology: Clinical and Experimental. 2006;21:393-8. PMID:16850522
  49. Kelly DL, Conley RR, Feldman S, Yu Y, McMahon RP, Richardson CM. Adjunct Divalproex or Lithium to Clozapine in Treatment-Resistant Schizophrenia. Psychiatric Quarterly. 2006;77(1):81-95. PMID:16397757
  50. Kelly DL, Conley RR. A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology. 2006;31;340-346. PMID:16198059
  51. Shim J-C, Shin J-G, Kelly DL, Jung D-U, Seo Y-S, Liu KH, Sohn J-H, Conley RR. Adjunctive Treatment With a Dopamine Partial Agonist, Aripiprazole, for Antipsychotic-Induced Hyperprolactinemia: A Placebo-Controlled Trial. American Journal of Psychiatry. 2007;164 (9):1310-2. PMID:17728426
  52. Conley RR, Kelly DL. Clinical Pharmacology and Medication-Associated Side Effects: A Review of Second-Generation Antipsychotics for Schizophrenia. Clinical Schizophrenia & Related Psychoses. 2007;3:135-146.
  53. Shim JC, Choe BM, Kim JG, Jae YM, Kim HC, Kim SG, Oh MK,Kelly DL, Conley RR.Discontinuation of Risperidone, Olanzapine, and Haloperidol in First Episode Psychosis. J Clin Psychopharmacol. 2007;27:400-401. PMID:17632229
  54. Kelly DL, Kreyenbuhl J, Buchanan RW, Malhotra MK. Why Not Clozapine? Clinical Schizophrenia & Related Psychoses. 2007;1:92-5.
  55. Conley RR, Kelly DL. Drug–drug Interactions Associated with Second-Generation Antipsychotics: Considerations for Clinicians and Patients. Psychopharmacology Bulletin. 2007;40:77-97. PMID:17285099
  56. Kelly, DL, Conley RR, Love RC, Morrison JA, McMahon RP. Metabolic Risk With Second-Generation Antipsychotic Treatment: A Double-Blind Randomized 8-week Trial of Risperidone and Olanzapine. Annals of Clinical Psychiatry. 2008;20:71-8. PMID:18568578
  57. Kelly DL, Weiner E, Conley RR, McMahon RP, Buchanan RW.  Lack of Beneficial Galantamine Effect for Smoking Behavior: A Double-Blind Randomized Trial in People with Schizophrenia. Schizophrenia Research. 2008;103;161-8. PMID:18550339
  58. Shim JC, Liu Y-S, Kelly DL. Aripiprazole Treatment Causes Extrapyramidal Side Effects but Not Prolactin Elevations: A Disconnect of the Striatal D2 Occupancy Story. J Clin Psychopharmacology. 2008;28(3):353-354. PMID:18480699
  59. Boggs DL, Kelly DL, Nelson MW, Yu Y, Feldman S, McMahon RP, Conley RR. Quetipine at High doses for Treatment Refractory Schizophrenia.  Schizophrenia Research. 2008;101:347-8. PMID:18281197
  60. McMahon RP, Kelly DL, Boggs DL, Li L, Hu Q, Davis JM, Carpenter WT. Feasibility of Reducing the Duration of Placebo-Controlled Trials in Schizophrenia Research. Schizophrenia Bull. 2008;34:298-301. PMID:18184634
  61. Boggs DL, Kelly DL, Love RC, McMahon RP, Conley RR. Comparison of Clozapine Response for Inpatients in the Research Setting versus Routine Clinical Practice. Psychiatric Quarterly. 2008;79(2):111-119. PMID:18214677
  62. Schwilke EW, Schwope DM, Karschner EL, Lowe RH, Darwin WD, Kelly DL,Goodwin RS, Gorelick DA, Huestis MA. Δ9-Tetrahydrocannabinol (THC), 11-Hydroxy-THC & 11-nor-9-Carboxy-THC Plasma Pharmacokinetics During and Following Continuous High Dose Oral THC. Clinical Chemistry. 2009;55:2180-9. PMID: 19833841
  63. Kelly DL, Buchanan RW, Boggs DL, McMahon RP, Nelson M, Dickinson D, Gold JM, Ball MP, Feldman S, Liu F, Conley RR. A randomized double blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. J Clinical Psychiatry. 2009;70(4):518-25. PMID: 19358788.
  64. Kelly DL, Linthicum J, Wehring HJ, Feldman S, McMahon RP, Lover RC, Wagner T, Shim J-C, Fowler DR. Cardiac-Related findings at autopsy in people with severe mental illness treated with clozapine or risperidone. Schizophrenia Research. 2009;107:134-8. PMID:19028422
  65. Conley RR, Boggs DL, Kelly DL, McMahon RP, Feldman S, Ball P, Buchanan RW. The Effects of Galantamine on Psychopathology in Chronic Stable Schizophrenia. Clinical Neuropharmacology. 2009;32;69-74. PMID:18978489
  66. Kelly DL, Weiner E, Ball MP, McMahon RP, Carpenter WT, Buchanan RW. Remission in Schizophrenia: The Relationship to Baseline Symptoms and Changes in Symptom Domains During a One-Year Study. J of Psychopharmacology. 2009:23;436-41. PMID:18583442
  67. Kelly DL, McMahon RP, Liu F, Love RC, Wehring HJ, Shim JC, Warren KR, Conley RR. Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. J Clin Psychiatry. 2010;71:304-11. PMID: 20079332
  68. Kelly DL, Feldman S, Boggs DL, Gale E, Richardson CM, Conley RR. Nonresponse to clozapine and premorbid functioning in treatment of refractory schizophrenia. Comprehensive Psychiatry. 2010;51;298-302. PMID 20399340
  69. Wehring HJ, Liu F, McMahon RP, Spieker EA, Warren KR, Boggs DL, Love RC, Dickinson D, Shim JC, Fowler D, Kelly DL. The relationship of brain weight to body mass index (BMI) upon autopsy in young people with severe mental illness. Schizophrenia Research. 2010;123:86-7.  PMID:20800997
  70. Weiner E, Conley RR, Ball MP, Feldman S, Gold JM, Kelly DL, Wonodi I, McMahon RP, Buchanan RW. Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine Neuropsychopharmacology. 2010;35;2274-83. PMID: 20664583
  71. Milman G, Barnes AL, Schwope DM, Schwilke EW, Darwin WD, Goodwin RS, Kelly DL, Gorelick DA, Huestis MA.  Disposition of Cannabinoids in Oral Fluid Following Controlled Around-the-Clock Oral THC Administration. Clinical Chemistry. 2010;56:1261-9. PMID: 20530732
  72. Levin KH, Copersino ML, Heishman SJ, Liu F, Kelly DL, Boggs DL, Gorelick DA. Cannabis Withdrawal Symptoms in Non-Treatment-Seeking Adult Cannabis Smokers.  Drug and Alcohol Dependence. 2010;111:120-7. PMID: 20510550
  73. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Fischer BA, Himelhoch S, Boggs DL, Fang B, Peterson E, Aquino PR, Keller W. The 2009 SchizophreniaPORT Psychopharmacological Treatment Recommendations and Summary Statements. Schizophr Bull. 2010;36;71-93. PMID: 19955390
  74. Wehring HJ, Thedford S, Koola M, Kelly DL. Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia Disease. 2011;3:107-23. PMID: 23293546
  75. Jung DU, Kelly DL, Oh MK, Kong BG, Kang JW, Lee SJ, Shim JC: Bone Mineral Density and Osteoporosis Risk in Older Patients With Schizophrenia. J Clinical Psychopharmacology. 2011;31:406-10. PMID: 21694624
  76. Kelly DL, Myers CS, Abrams MT, Feldman S, Park J, McMahon RP, Shim JC. The impact of substance abuse on osteoporosis screening and risk of osteoporosis in women with psychotic disorders. Osteoporosis Int. 2011;22(4):1133-43. PMID: 20533029
  77. Milman G, Barnes AJ, SchwopeDM, Schwilke EW, Goodwin RS, KellyDL, GorelickDA,  Huestis MA: Cannabinoids and metabolites in expectorated oral fluid after eight days of controlled around-the-clock oral THC administration. Analytical and Bioanalytical Chemistry, 2011;401:599-607. PMID: 21637933
  78. Cascella NG, Kryszak D, Bhatti B, Gregory P, Kelly DL, Mc Evoy JP, Fasano A, Eaton WW. Prevalence of celiac disease and gluten sensitivity in the United States Clinical Antipsychotic Trials of Intervention Effectiveness Study Population. Schizophr Bull. 2011;37:94-100, PMID:19494248.
  79. Ball MP, Warren KR, Feldman S, McMahon RP, Kelly DL, Buchanan RW: Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine. Clin Schizophr Relat Psychoses. 2011. Apr;5(1):17-25. PMID: 21459735
  80. Lo S, Raley HG, Heishman SJ, Wright K, Wehring HJ, Moolchan ET, Feldman S, Liu F, McMahon RP, Richardson CM, Kelly DL. Cigarette Craving and Dependency in People with Schizophrenia Compared to Normal Controls. Schizophrenia Research. 2011;127:241-5. PMID: 20637571.
  81. Kelly DL, McMahon RP, Wehring H, Liu F, Mackowick K, Boggs DL, Warren KR, Feldman S, Shim JC, Love RC, Dixon L. Cigarette smoking and mortality risk in people with schizophrenia. Schizophr Bulletin. 2011;37:832-8, PMID: 20019128
  82. Weiner E, Buchholz A, Coffay A, Liu F, McMahon RP, Buchanan RW, Kelly DL. Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study.  Schizophr Res. 2011 Jun;129(1):94-5. PMID: 21376537
  83. Kelly DL, Gorelick DA, McMahon RP, Boggs DL, Linthicum J, Liu F, Feldman S, Ball MP, Richardson CM, Conley RR, Gold JM, Wehring HJ, Kearns AM, Huestis MA, Buchanan RW. Effects of the Cannabinoid-1 Receptor Antagonist Rimonabant on Psychiatric Symptoms In Overweight People with Schizophrenia: A Randomized, Double-Blind Pilot Study, J Clinical Psychopharmacology, 2011;31:86-91 PMID: 21192149
  84. Warren KR, Ball MP, Feldman S, Liu F, McMahon RP, Kelly DL. Exercise program adherence using a 5-kilometer event and an achievable goal in people with schizophrenia.             Biol Res Nurs 2011;13:383-90. PMID: 21196420
  85. Kelly DL, Vyas G, Richardson CM, Koola MM, McMahon RP, Buchanan RW, Wehring HJ. Adjunct Minocycline to Clozapine in Treatment Resistant Schizophrenia. Schizophrenia Research. 2011;13:257-8. PMID: 21872445
  86. Gorelick DA, Goodwin RS, Schwilke E, Schwope DM, Darwin WD, Kelly DL, McMahon RP, Liu F, Ortemann-Renon C, Bonnet D, Huestis MA. Antagonist-elicited cannabis withdrawal in humans. J Clin Psychopharmacol 2011;31:603-12. PMID: 251869692
  87. Kelly DL, Thedford S, Vyas G. A new blood-based diagnostic aid for schizophrenia. Psychiatr Serv 2011;62:1107. PMID: 21885596
  88. Milman G, Schwope DM, Schwilke EW, Darwin WD, Kelly DL, Goodwin RS, Gorelick DA, Huestis MA. Oral fluid and plasma cannabinoid ratios afer around-the-clock controlled oral [delta]9-tetrahydrocannabinol administration. Clin Chem 2011;57:1597-606. PMID: 21875944
  89. Goodwin RS, Baumann MH, Gorelick DA, Schwilke E, Schwope DM, Darwin WD, Kelly DL, Schroeder JR, Ortemann-Renon C, Bonnet D, Huestis MA. CB1-Cannabinoid receptor          antagonist effects on Cortisol in cannabis-dependent men. Am J Drug Alcohol Abuse 2012;38:114-9 PMID: 2179781
  90. Koola M, Fawcett JA, Kelly DL. Case report on the management of depression in schizoaffective disorder, bipolar type focusing on lithium levels and measurement based care. Journal of Nervous and Mental Disease, 2011;199:989-990.  PMID: 22134460
  91. Wehring HJ, Thedford S. Koola M, Kelly DL. Patient and health care provider perspectives on long acting antipsychotics in schizophrenia and the introduction of olanzapine long acting injection. J Cent Nerv Syst Dis 2011;3:107-123. PMID: 23293546
  92. Jackson J, Eaton W, Cascella N, Fasano A, Kelly DL.  Neurologic and Psychiatric Manifestations of Celiac Disease and Gluten Sensitivity.  Psychiatric Quarterly.  2012;83:91-102.  PMID: 21877216.
  93. Boggs DL, Kelly DL, RP McMahon, Gold JM, Gorelick DA, Linthicum J, Conley RR, Liu F, Waltz J, Huestis MA, Buchanan RW. Rimonabant for neurocognition in schizophrenia: a 16 week double blind randomized placebo controlled trial. Schizophr Res, 2012;134:207-10. PMID: 22137462
  94. Shim JC, Jung DU, Jung SS, Seo YS, Cho DM, Lee JH, Lee SW, Kong BG, Kang JW, Oh MK, Kim SD, McMahon RP, Kelly DL.  Adjunctive Varenicline Treatment with Antipsychotic Medications for Cognitive Impairments in People with Schizophrenia:  A Randomized Double-Blind Placebo-Controlled Trial.  Neuropsychopharmacology 2012;37:660-668  PMID:  22048460
  95. Koola MM, Brown WV, Qualls C, Cuthbert B, Hollis JP, Kelly DL, Le NA, Raines J, Duncan EJ. Reduced arterial compliance in patients with psychiatric diagnoses. Schizophr Res 2012; 137:251-3. PMID: 22377105
  96. Gorelick D, Levin KH, Copersino ML, Heishman SJ, Liu F, Boggs DL, Kelly DL. Diagnostic criteria for cannabis withdrawal syndrome. Drug and Alcohol Dependence, 2012:123:141-7. PMID: 22153944
  97. Karschner EL, Schwope DM, Schwilke EW, Goodwin RS, Kelly DL, Gorelick DA, Huestis MA. Predictive model accuracy in estimating last D(9)-tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC. Drug Alcohol Depend 2012;125:313-9. PMID: 22464363.
  98. Abrams M, Myers C, McMahon RP, Kelly DL. Cervical cancer screening and associated acute care rates for Medicaid enrollees with mental and substance use disorders. Psychiatric Services, 2012;63:815-22. PMID: 22666450.
  99. Kelly DL, Wehring HJ, Vyas G. The current use of clozapine in the US. Shanghai Arch of Psychiatry, 2012;24:110-113.
  100. Mackowick KM, Heishman SJ, Wehring HJ, Liu F, McMahon RP, Kelly DL. Illicit drug use in heavy smokers with and without schizophrenia. Schizophr Res, 2012;139:194-200.  PMID: 22591779.
  101. Wehring HJ, Liu F, McMahon RP, Mackowick KM, Love RC, Dixon L, Kelly DL. Clinical characteristics of heavy and non-heavy smokers with schizophrenia. Schizophr Res 2012:138:285-9. PMID: 22578720
  102. Koola M, Wehring HJ, Kelly DL. The potential role of long acting injectable antipsychotics in dually diagnosed people with schizophrenia. Journal of Dual Diagnosis, 2012;8:50-61. PMID: 22754405
  103. Abrams MT, Myers CS, Feldman SM, Boddie-Willis C, Park K, McMahon RP, Kelly DL. Cervical cancer screening and acute care visits among Medicaid enrollees with mental and substance use disorders. Psychiatr Serv 2012;63:815-22. PMID: 22660581
  104. Koola MM, McMahon RP, Wehring HJ, Liu F, Mackowick KM, Warren KR, Feldman S, Shim JC, Love RC, Kelly DL. Alcohol and cannabis use and mortality in people with schizophrenia and related psychotic disorders. J Psychatriat Res 2012;46:987-93. PMID: 22595870.
  105. Kelly DL, Raley H, Lo S, Wright K, Moolchan E, Feldman S, Liu F, McMahon RP, Richardson CM, Jaszyna-Gasior M, Wehring HJ, Boggs D, Heishman S. Perception of smoking risks and motivation to quit among nontreatment-seeking smokers with and without schizophrenia. Schizophrenia Bull. 2012;38:543-51.  PMID: 21041835
  106. Jackson J, Eaton W, Cascella N, Fasano A, Warfel D, Feldman D, Richardson C, Vyas G, Linthicum J, Santora D, Warren KR, Carpenter WT, Jr, Kelly DL. A gluten free diet in people with schizophrenia and anti-tissue transglutaminase or anti-gliadin antibodies. Schizophr Res 2012;140:262-3. PMID: 22771303
  107. Keller WR, Kum LM, Wehring HJ, Koola MM, Buchanan RW, Kelly DL. A review of anti-inflammatory agents for symptoms of schizophrenia. J Psychopharmacol 2013;27:337-42. PMID: 23151612.
  108. Boggs DL, Kelly DL, Liu F, Linthicum J, Turner H, Schroeder JR, McMahon RP, Gorelick DA. Cannabis withdrawal in chronic cannabis users with schizophrenia. J Psychiatr Res 2013;47:340-5. PMID: 23146560
  109. Gorelick DA, Goodwin RS, Schwilke E, Schwope DM, Darwin WD, Kelly DL, McMahon RP, Liu F, Ortemann-Renon C, Bonnet D, Huestis MA. Tolerance to Effects of High-Dose Oral [Delta}9-Tetrahydrocannabinol and Plasma Cannabinoid Concentrations in Male Daily Cannabis Smokers. J Anal Toxicol 2013;37:11-6. PMID:  2307421
  110. Cascella NG, Santora D, Gregory P, Kelly DL, Fasano A, Eaton WW. Increased prevalence of transglutaminase 6 antibodies in sera from schizophrenia patients. Schizophr Bull 2013;39:867-71. PMID: 22516148
  111. Warren KR, Buchanan RW, Feldman S, Conley RR, Linthicum J, Ball MP, Liu F, McMahon RP, Gorelick DA, Huestis MA, Kelly DL. Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind pilot study. J Clin Psychopharmacol 2013;33:118-20.  PMID:  23277241.
  112. Okusaga O, Yolken RH, Langenberg P, Sleemi A, Kelly DL, Vaswani D, Giegling I, Hartmann AM, Konte B, Friedl M, Mohyuddin F, Groer MW, Rujescu D, Postolache TT. Elevated gliadin antibody levels in individuals with schizophrenia. World J Biol Psychiatry 2013;14:509-15. PMID: 23282016.
  113. Lee MR, Wehring HJ, McMahon RP, Linthicum J, Cascella N, Liu F, Bellack A, Buchanan RW, Strauss GP, Contoreggi C, Kelly DL. Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: Results from a randomized double blind placebo controlled pilot study. Schizophr Res. 2013;145:110-5. PMID: 23415472
  114. Koola MM, Qualls C, Kelly DL, Skelton K, Bradley B, Amar R, Duncan EJ. Prevalence of  childhood physical and sexual abuse in veterans with psychiatric diagnoses. J Nerv Ment Dis 2013;201:348-52. PMID: 23538982
  115. Koola MM, Boggs DL, Kelly DL, Linthicum JA, Turner HE, McMahon RP, Gorelick DA.  Relief of cannabis withdrawal symptoms and cannabis quitting strategies in people with schizophrenia. Psychiatry Res 2013;30:273-8. PMID: 23969281
  116. Kelly DL, Wehring HJ, Earl AK, Sullivan K, Dickerson FB, Feldman S, McMahon RP, Buchanan RW, Warfel D, Keller WR, Fischer BA, Shim JC.   Treating symptomatic hyperprolactinemia in    women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic Elevated proactin).  BMC Psychiatry 2013;13:214 PMID: 23968123.
  117. Gorelick DA, Goodwin RS, Schwilike E, Schoreder JR, Schwope DM, Kelly DL, Ortemann-    Renon C, Bonnet D, Huestis MA. Around the clock oral THC effects on sleep in male chronic  daily cannabis smokers. Am J Addict 2013;22:510-4.  PMID:  23952899.
  118. Wehring HJ,  Perez G, Dixon L, Kelly DL. Women and Drug and Alcohol Use Disorders: Compounding the Picture with Severe Mental Illness. Current Women’s Health Reviews 2013; 9(3):183-188.
  119. Ben-Yoav H, Winkler TE, Kim E, Chocron SE, Kelly DL, Payne GF, Ghodssi R.  Redox cycling- based amplifying electrochemical sensor for in situ clozapine antipsychotic treatment monitoring. Electrochimica Actra 2014;130:497-503.
  120. Koola MM, Gorelick DA, McMahon RP, Liu F,  Huestis M, Linthicum J, Feldman S, Warren KR, Wehring HJ, Kelly DL. Psychiatric symptom differences in people with schizophrenia associated with substantial lifetime substance use but no current substance use disorder, Schizophr Res 2014; 152:315-316.  PMID:  24333005.
  121. Warren KM, Postolache TT, Groer ME, Pinjari O, Kelly DL, Reynolds MA. Role of chronic stress and depression in periodontal diseases. Periodontol 2000 2014 Feb; 64(1):127-138. PMID:  24320960.
  122. Goldstein JI, Fredrik Jarskog L, Hilliard C, Alfirevic A, Duncan L, Fourches D, Huang H, Lek M, Neale BM, Ripke S, Shianna K, Szatkiewicz JP, Tropsha A, van den Oord EJ, Cascorbi I, Dettling M, Gazit E, Goff DC, Holden AL, Kelly DL, Malhotra AK, Nielsen J, Pirmohamed M, Rujescu D, Werge T, Levy DL, Josiassen RC, Kennedy JL, Lieberman JA, Daly MJ, Sullivan PF. Clozapine –induced agranulocytosis is associated with rare HLA-DQB1 and HLA alleles. Nat Commun 2014;5:4757. PMID: 25187353.
  123. Lee MR, Glassman M, King-Casas B, Kelly DL, Stein EA, Schroeder J, Salmeron BJ. Complexity of oxytocin’s effects in a chronic cocaine dependent population. Eur Neuropsychopharmacol 2014;9:1483-91. PMID: 25044050.
  124. Yu M, Hassan HE, Ibrahim A, Bauer KS, Kelly DL, Wang JB. Simultaneous determination of l-tetrahydroplamatine and cocaine in human plasma by simple UPLC-FLD method: Application to clinical studies. J Chromatogr B Analyt Technol Biomed Life Sci 2014;15:965-44. PMID: 24996068.
  125. Jackson J, Eaton W, Cascella N, Fasano A, Santora D, Sullivan K, Feldman S, Raley H, McMahon RP, Carpenter WT Jr, Demyanovich H, Kelly DL. Gluten Sensitivity and relationship to psychiatric symptoms in people with schizophrenia. Schizophr Res 2014;159:539-42. PMID: 25311778.
  126. Winkler T, Ben-Yoav H, Chocron S, Kim E, Kelly DL, Payne G, Ghodssi R. Electrochemical Study of the Catechol-modified Chitosan System for Clozapine Treatment Monitoring. Langmuir 2014;30:14686-93.
  127. Fischer BA, McMahon RP, Kelly DL, Wehring HJ, Meyer WA, Feldman S, Carpenter WT, Gorelick DA. Risk-taking in schizophrenia and controls with and without cannabis dependence. Schizophr Res 2015;161:471-7. PMID: 25467541.
  128. Evins AE, Hong LE, Kelly DL. T. Kishi and N. Iwata: Varenicline for smoking cessation in people with schizophrenia: systematic review meta-analysis. Eur Arch Psychiatry Clin Neurosci 2015;265:269-70. PMID: 25377170.
  129. Ben-Yoav H, Chocron SE, Winkler TE, Kim E, Kelly DL, Payne GF, Ghodssi R.  An electrochemical micro-system for clozapine antipsychotic treatment monitoring.  2015 May; (163):260-270.
  130. Buchanan RW, Weiner E, Kelly DL, Gold JM, Keller WR, Waltz JA, McMahon RP, Gorelick DA. Rasagiline in the treatment of persistant negative symptoms of schizophrenia. Schizophr Bull 2015;41:900-8. PMID: 25368372.
  131. Chocron SE, Weisberger BM, Ben-Yoave H, Winkler TE, Kim E, Kelly DL, Payne GF, Ghodssi R. Multi-deimensional mapping method using an arrayed sensing system for cross reactivity screening. PLoS One  2015;10:e0116310.  PMID: 25789880.
  132. Eaton WW, Chen LY, Dohan FC Jr. Kelly DL, Cascella N. Improvement in psychotic symptoms after a gluten-free diet in a boy with complex autoimmune illness. Am J Psychiatry 2015;172:219-21. PMID: 25727533.
  133. Kim E, Chocron SE, Ben-Yoav H, Winkler TE, Liu Y, Glassman M, Wolfram C, Kelly DL, Ghodssi R, Payne GF.  Programmable “semismart” sensor:  relevance to monitoring antipsychotics.  Adv Funct Mater, 2015;25:2156-2165.
  134. Kelly, DL, Sullivan KM, McEvoy JP, McMahon RP, Wehring HJ, Liu F, Warfel D, Vyas G, Richardson CM, Fischer BA, Keller WR, Koola MM, Feldman, SM, Russ JC, Keefe RS, Osing J, Hubzin L, August A, Walker TM, Buchanan RW.  Adjunctive Minocycline in clozapine treated schizophrenia patients with persistent symptoms. J Clin Psychopharmacol. 2015 Aug;35(4):374-81. doi: 10.1097/JCP.0000000000000345. PMID: 26082974
  135. Miller J, Wehring H, McMahon R, DiPaula B, Love R, Davies K, Morris AA, Raley H, Feldman S, Warfel D, Kelly DL.  Urine testing for antipsychotics: a pilot trial for a method to determine detection levels. Hum Psychopharmacol. 2015 Sep;30(5):350-5. doi: 10.1002/hup.2482. Epub 2015 May 25. PMID: 26010339.
  136. Eaton WW, Chen LY, Dohan FC, Jr, Kelly DL, Cascella N. Response to Ell’Osso and Elli. Am J Psychiatry. 2015 Jul;172(7):686. PMID: 26130205
  137. Kelly DL*, Ben-Yoav H*, Payne GF, Winkler TE, Chocron SE, Kim E, Stock V, Yvas G, Love RC, Wehring HJ, Sullivan KM, Feldman SF, Liu F, McMahon RP, Ghodssi R.  Blood draw barriers for treatment with clozapine and development of point-of-care monitoring device. Clinical Schizophrenia & Related Disorders, 2015 Jul 28. [Epub ahead of print] PMID: 26218235.
  138. Koola MM, Sullivan KM, Earl AK, Feldman SM, Richardson CM, Vyas GR, Wehring HJ, Kelly DL.  Undiagnosed Lyme disease in adults with schizophrenia. Schizophr Res. 2015 Oct;168(1-2):579-80. PMID: 26255567.
  139. Patchan KM, Richardson C, Vyas G, Kelly DL.  The risk of suicide after clozapine discontinuation: cause for concern.  Ann Clin Psychiatry, 2015 Nov; 27(4):253-256.  PMID: 26554366.
  140. Kelly DL, Rowland LM, Patchan KM, Sullivan K, Earl A, Raley H, Liu F, Feldman S, McMahon RP.  Schizophrenia clinical symptom differences in women vs men with and without a history of childhood physical abuse.  Child Adolesc Psychiatry Ment Health.  2016;10(5):doi: 10.1186/s13034-016-0092-9.  PMID:  26941836
  141. Lee MR, Wehring HJ, McMahon RP, Liu F, Linthicum J, Verbalis JG, Buchanan RW, Strauss GP, Rubin LH, Kelly DL.  Relationship of plasma oxytocin levels to baseline symptoms and symptom changes during three weeks of daily oxytocin administration in people with schizophrenia.  Schizophr Res 2016;172(1-3):165-8.  PMID:  26879587
  142. Okusaga, O, Fuchs, D, Reeves G, Giegling I, Hartmann AM, Konte B, Friedl M, Groer M, Stearns-Yoder KA, Pandey JP, Kelly DL, Hoisington AJ, Lowry CA, Eaton WW, Brenner LA, Rujescu D, Postolache TT.  Kynurenine and trypophan levels in patients with schizophrenia and elevated anti-gliadin immunoglobulin G antibodies.  Psychosomatic Medicine.  2016;78:931-939. PMID: 27359171
  143. Koola MM, Kelly DL, McMahon RP, Boggs DL, Liu F, Gorelick DA.  Psychoactive substance use by adults with schizophrenia before and during cannabis withdrawal.  Prim Care Companion CNS Disord. 2016 Sep 1;18(5).  PMID:  27835727
  144. Legge SE, Hamshere ML, Ripke S, Pardinas AF, Goldstein JI, Rees E, Riahcards AL, Leonenko G, Jarskog LF, Clozapine-Induced Agranulocytosis Consortium. Genome-wide common and rare variant analysis provides novel insights into clozapine-associated Neutropenia. Mol Psychiatry 2016 epub ahead of print  PMID: 27400856
  145. Norman SM, Sullivan KM, Liu F, DiPaula BA, Jose PA, Kitchen CA, Feldman SM, Kelly DL. Blood pressure and heart rate changes during clozapine treatment. Psychiatr Q 2016, epub ahead of print. PMID: 27678498
  146. Richardson CM*, Davis EA,* Vyas GR, DiPaula BA, McMahon RP, Kelly DL. Evaluation of the safety of clozapine use in patients with benign neutropenia.  J Clin Psych 2016;77(11):e1454-e1459.  PMID: 27736047.
  147. Koola MM, Kelly DL, McMahon RP, Boggs D, Liu F, Gorelick DA. Substance use by adults with schizophrenia before and during cannabis withdrawal.  Prim Care Companion CNS Disord. 2016;18(5).  PMID:  27835727
  148. Kowalczyk WJ, Wehring HJ, Burton G, Raley H, Feldman S, Heishman SJ, Kelly DL.  Predictors of the perception of cigarette health risks in smokers with and without schizophrenia.   J of Dual Diagnosis.  2017 Jan-Mar;13(1)29-35.  PMID: 27858591
  149. Kim E, Liu Y, Ben-Yoav H, Winkler TE, Yan K, Shi X, Shen J, Kelly DL, Ghodssi R, Bentley WE, Payne GF.  Fusing sensor paradigms to acquire chemical information: an integrative role for smart biopolymeric hydrogels.  Adv Healhcare Materials 2016;5:2595-2616. PMID: 27616350
  150. Fiorentino M, Sapone A, Senger S, Camhi SS, Kadzielski SM, Buie TM, Kelly DL, Cascella N, Fasano A. Blood-brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders. Mol Autism 2016:7:49. PMID: 27957319
  151. Shovestul B, Glassman M, Rowland LM, McMahon RP, Liu F, Kelly DL.  Pilot study examining the relationship of childhood trauma, perceived stress, and medication use to serum kynurenic acid and kynurenine levels in schizophrenia.  Schiz Research.  2017;185:200-1. PMID: 28082139
  152. Hassan HE*, Kelly DL*, Honick M, Shukla S, Ibrahim A, Gorelick DA, Glassman M, McMahon RP, Wehring HJ, Kearns AM, Feldman S, Yu M, Bauer K, Wang JB.  Pharmacokinetics and safety assessment of l-tetrahydropalmatine in cocaine users: a randomized, double-blind, placebo controlled study.  Clinical Pharmacology & Therapeutics. J Clin Pharmacol. 2017 Feb;57(2):  151-160.  PMID:  27363313.
  153. Xiang YQ, Zheng W, Wang SB, Yang XH, Cai DB, Ng CH, Ungvari GS, Kelly DL, Xu WY, Xiang YT.  Adjunctive Minocycline for schizophrenia: a meta-analysis of randomized controlled trials.  European Neuropsychopharmacology.  2017;27:8-18. PMID: 27919523
  154. Kim E, Winkler TE, Kitchen C, Kang M, Banis GE, Bentley WE, Kelly DL, Ghodssi R, Payne GF.  Redox probing for chemical information of oxidative stress.  Anal Chem 2017;89:1583-92. PMID: 28035805
  155. Wehring HJ, Heishman SJ, McMahon RP, Liu F, Feldman S, Raley H, Weiner E, Kelly DL.  Antipsychotic treatment and tobacco craving in people with schizophrenia.  Journal of Dual Diagnosis.  2017;13:36-42 PMID: 28166471
  156. Cohen AS, Mitchell KR, Strauss GP, Blanchard JJ, Buchanan RW, Kelly DL, Gold J, McMahon RP, Adams HA, Carpenter WT. The effects of oxytocin and galantamine on obejectivity-defined vocal and facial expression: data from the CIDAR study. Schizophr Res  2017;188:141-143. PMID: 28130004
  157. Kang M, Kim E, Winkler TE, Banis G, Liu Y, Kitchen CA, Kelly DL, Ghodssi R, Payne GF.  Reliable clinical serum analysis with reusable electrochemical sersor:  Toward point-of-care measurement of the antipsychotic medication clozapine.  Biosens Bioelectron.  2017 Apr 12;95:55-59.  PMID: 28412661
  158. Winkler TE, Lederer SL, Kim E, Ben-Yoav H, Kelly DL, Payne GF, Ghosssi R.  Molecular processes in an electrochemical clozapine sensor. Biointerphases. June 2017;12(2):02B401.
  159. Winkler TE, Dietrich R, Kim E, Ben-Yoav H, Kelly DL, Payne GF, Ghodssi R.The interplay of electrode- and bio-materials in a redox-cycling-based clozapine sensor.  Electrochemistry Communications.  Electrochemistry Communications.  2017 June (79):33-36. PMID: 28460529
  160. Buchanan RW, Kelly DL, Weiner E, Gold JM, Strauss GP, Koola MM, McMahon RP, Carpenter WT.  A randomized clinical trial of oxytocin or galantamine for the treatment of negative symptoms and cognitive impairments in people with schizophrenia.  J Clin Psychopharmacology 2017;37:394-400  PMID: 28590362
  161. Patchan K, Vyas G, Hackman AL, Mackowick M, Richardson CM, Love RC, Wonodi I, Sayer MA, Glassman M, Feldman S, Kelly DL.  Clozapien in reducing aggression and violence in forensic populations. Psych Quarterly 2017. Epub ahead of print.  PMID: 28643049
  162. Wehring HJ, Elsobky T, McEvoy JP, Vyas G, Richardson CM, McMahon RP, DiPaula BA, Liu F, Sullivan K, Buchanan RW, Feldman S, McMahon RP, Kelly DL. Adjunctive minocycline in clozapine-treated patients with schizophrenia: analyzing the effects of minocycline on clozapine plasma levels. Psych Quarterly 2017; epub ahead of print. PMID: 28466366
  163. Cihakova D, Eaton WW, Talor MV, Harkus UH, Demyanovich H, Rodriguez K, Feldman S, Kelly DL.   Gliadin-related antibodies in schizophrenia. Schizophrenia Research, 2017, epub ahead of print  PMID: 28886891
  164. Banis GE, Winkler TE, Barton P, Chocron SE, Kim E, Kelly DL, Payne GF, Ben-Yoav H, Ghodssi R. The binding effects of proteins on medications and its impact on electrochemical sensing: antipsychotic clozapine as a case study.  Pharmaceuticals. 2017;10: pii: E69. doi: 10.3390/ph10030069. PMID: 28763030
  165. Kang M, Kim E, Winkler TE, Banis G, Liu F, Kitchen C, Kelly DL, Ghodssi R, Payne GF.  Electrodeposited graphene-chitosan composite film for therapeutic drug monitoring.  Biosens Bioelectron.  2017;95:55-59  PMID   28412662.
  166. Rowland LM, Demyanovich HA, Witjenberg SA, Eaton WW, Rodriguez K, Gaston F, Cihakova D, Talor MV, Liu F, McMahon RP, Hong LE, Kelly DL.  Antigliadin Antibodies (AGA IgG) Are Related to Neurochemistry in Schizophrenia. Frontiers in Psychiatry 2017:8:104  PMID 28674804
  167. Temocin Z, Kim E, Li J, Panzella L, Alfierei ML, Japolitano A, Kelly DL, Bently WE, Payne GF. The analgesic acetaminophen and antipsychotic clozapine can each redox-cycle with melanin. ACS Chem Neuroscien 2017, epub ahead of print. PMID 28945963
  168. Kelly DL, Freudenreich O, Sayer MA, Love RC. Addressing barriers to clozapine underutilization: a national effort. Psychiatr Serv 2017, epub ahead of print. PMID  29032704.
  169. Rubin LH, Wehring HJ, Demyanovich H, Carter S, Pournajafi-Nazarloo H, Feldmand SM, Earl AK, August S, Gold JM, Kelly DL. Peripheral oxytocin and vasopressin are associated with clinical symptom severity and cognitive functioning in midlife women and chronic schizophrenia. Schizophr re 2017, epub ahead of print. PMID   289657765
  170.  Liu Y, Li J, Tschirhart T, Terrell JL, Kim E, Tsao CY, Kelly DL, Bentley WE, Payne GF. Connecting biology to electronics: molecular communication via redoz modality. Adv Healthc Mater 2017, epub ahead of print.   PMID 29045017
  171. Kelly DL, Demyanovich HK, Eaton W, Cascella N, Jackson J, Fasano A, Carpenter WT. Antigliadin antibodies (AGA IgG) related to peripheral inflammation in schizophrenia. Brain Behav Immun 2017, epub ahead of print. PMID  29074356

Research Interests

Dr. Kelly has been involved in numerous clinical trials for the treatment for schizophrenia and has been active in psychopharmacology research for the past 20 years. She has evaluated many novel medications and strategies in schizophrenia, most recently completing clinical trials with adjunctive minocycline, an antibiotic with anti-inflammatory properties and a clinical trial, the DAAMSEL trial, testing adjunct aripiprazole vs. placebo in premenopausal women with symptomatic hyperprolactinemia. She just received funding for a confirmatory study to study a gluten free diet in patients who are positive for antigliadin antibodies, a possible biomarker for efficacy in this subpopulation. She also is studying the safety of clozapine in Benign Ethnic Neutropenia as well as a handful of other clinical trials. 

Dr. Kelly has been a proponent for more widespread use and currently is working on understanding barriers to current use, develop monitoring devices and study ways to better deliver treatment. She has a history in studying side effects and efficacy in numerous clinical studies with clozapine.

Awards and Affiliations

Honors and Awards

1998                NIMH New Investigator’s Award, awarded at the New Clinical Drug Evaluation Unit (NCDEU) meeting

1999                Future Leaders in Psychiatry Award Selection, EmoryUniversity and Janssen Pharmaceutica

2001                Young Investigator Award, International Congress of Schizophrenia Research

2008                “Heroes in the Fight” Team Award awarded to the Treatment Research Program by NAMI, 12 other organizations and Eli Lilly

2008                MM&M Award, Clinical Schizophrenia and Related Psychosis awarded for Best New Business Healthcare Publication; serve as founding Associate Editor

2010                Best Medical Book Award, American Writers Association awarded for Pharmacotherapy Principles and Practice, 2nd Edition. Authored Schizophrenia Chapter

2015                Best Poster Award, Mid-Atlantic Micro-Nano Alliance Spring Workshop, 2015, Thomas Winkler, lead author and presenter

2015                Honorable Mention Poster Award, Psychiatry Research Day, Spring 2015, Erica Davis, lead author and presenter.

2016                President-Elect, College of Psychiatric and Neurologic Pharmacists

2016                Professor with Tenure, University of Maryland School of Medicine

2017                President, College of Psychiatric and Neurologic Pharmacists

2017                Maltz Prize for Innovative & Promising Schizophrenia Research, Brain and Behavior Research Foundation

Grants and Contracts

Active Grants:

 

 8/1/2017-7/31/22       Deanna Kelly (PI: 20%)

                                    “Confirmatory Double-Blind Placebo-Controlled Efficacy Trial of Gluten-Free Diet in a Subgroup of Persons with Schizophrenia Who Have High Levels of IgG Anti-                                            Gliadin Antibodies”

                                    NIMH  # 1R01 MH113617-01

 

6/2017-5/31/2019        Ben-Yoav, Hadar PI; Kelly, Deanna L.: Role – Mentor, No Salary Support

                                    Real-Time Monitoring of Clozapine Levels in Capillary Blood

                                    Brain & Behavior Research Foundation (NARSAD Grant # 74804)

Total Costs: 70,000

 

7/1/12-6/30/18             Deanna Kelly (Co-investigator 16%) PI: Raymond C. Love

                                     State of Maryland Medicaid Contract, Antipsychotic Utilization Review       

                                   

04/15/13 – 03/31/18    Deanna Kelly (Mentor-no salary support) Heidi Wehring (PI)                       

                                    “Tobacco Craving in Smokers with Schizophrenia”

                                    NIDA 1K23 DA034034-01A1

                                   

 

04/01/14 – 03/31/18    Kelly, Deanna (1%) (PI)

                                    “Treatment of Schizophrenia with ltetrahydropalmatine (l-THP): a Novel  Dopamine Antagonist with Anti-Inflammatory and Antiprotozoal Activity”

                                    Stanley Medical Research Institute (SMRI), Grant# 13-007

                                    

04/01/14 – 03/31/19    Deanna Kelly (15%) (Co-Investigator, Project 4) Robert Schwarcz (PI)   “Kynurenic Acid and Cognitive Abnormalities in Schizophrenia”

                                    Silvio O. Conte Centers for Basic or Translational                

                                    NIMH P50 MH103222                                                           

                                                     

01/01/15 – 12/31/17    Kelly, Deanna, (PI, 15%); Ghodssi, Reza (Co-PI)    

                                 “Microsystem Development for Clozapine Monitoring in Schizophrenia”

                                   NIMH R56 Bridge Award to R01 MH105571-01

 

04/01/15 – 03/31/19    Kelly, Deanna (PI, 18%)

                                    “Biomarker and Safety Study of Clozapine in Benign Ethnic Neutropenia” 

                                    NIMH R01 MH102215                                               

                                   

2016-2018                   Kelly, Deanna; Resnik, Phillip (Co-PIs), UMCP/UMB Innovation Seed Grant, 

                                    “Development of Computational Modeling to Identify Symptom Changes in Schizophrenia and Depression”

                                 

04/01/14 – 03/31/19    Kelly, Deanna (Co-Investigator, Project 2) Robert Schwarcz (PI) “Kynurenic Acid and Cognitive Abnormalities in Schizophrenia”

                                    Silvio O. Conte Centers for Basic or Translational                

                                    NIMH P50 MH103222                                                           

                                    

 

12/15/16-11/30/19       Himelhoch, Seth (PI) Role: Co-Investigator 10%

                                    “Optimizing Smoking Cessation Treatments in Smokers Living with HIV/AIDS”

                                    NIMH #: 1R01HL136253-01

                                   

                                   

7/1/2017 – 6/30/2021  Carpenter, William; Rowland, Laura (MPIs) Role: Mentor 1% (no salary support) Multidisciplinary Schizophrenia Research Training (T32)

                                    NIH #: 5 T32 MH067533-12

                                    

4/2017 – 3/2018          Kelly, Deanna (PI) 7%

                                    A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of                                                   Schizophrenia ACP-103-034

                                  

Completed Grants:

1997-2004                   Deanna Kelly (Co-investigator: 20%) PI:  R. Conley

                                 “New Antipsychotic Strategies: Quetiapine And Risperidone Vs. Fluphenazine In Treatment-Resistant Schizophrenia”

                                    NIMH MH47311         

                       

 

1998-2000                   Deanna Kelly (Co-principal investigator: 15%) PI:  R. Conley 

                                      “Determining The Effectiveness Of Novel Antipsychotic Agents”.

                                     Stanley Medical Research Institute

                        

 

1999-2001                   Deanna Kelly (PI: 20%)

                                    “Sexual Function and Prolactin Levels With Atypical Antipsychotics”

                                    Stanley Medical Research Institute.

                       

 

1999-2000                   Deanna Kelly (PI: 5%)

                                    “Clinical And Laboratory Parameters Associated With Weight Gain With  Atypical Antipsychotic Treatment”

                                     NIMH Intervention Research Center (IRC) pilot grant

                        

 

2000-2001                   Deanna Kelly (PI: 20%)

                                   “An Evaluation of Clozapine Discontinuation In The Public Mental Health System In Maryland” UMB DRIF Award

                      

 

2001-2004                   Deanna Kelly (Co-Investigator: 10%) PI: Matthew Nelson

                                    “Atomoxetine as an Adjunct to Novel Antipsychotic Medications in the   Treatment of Cognitive Deficits of Schizophrenia”

                                    Stanley Medical Research Institute (01T-78)

                                    

 

2003-2005                   Deanna Kelly (PI: 30%)

                                    “Cardiac-Related Mortality with Atypical Antipsychotics”

                                    NIMH (R03 MH069871-02)

                       

 

2003-2008                   Deanna Kelly (Co-Investigator: 15%) PI:  W. Carpenter

                                    “Advanced Center for Intervention and Services Research (ACISR)”

                                    NIMH  (P50 MH40279)

                      

 

2003-2004                   Deanna Kelly (PI: 5%)

                                     “Adjunctive Divalproex To Clozapine In Treatment-Resistant  Schizophrenia”                                               

                                    Abbott Laboratories    

                      

 

2004-2005                   Deanna Kelly (PI: 5%)

                                    “The Utilization And Dosing Of Quetiapine In A Public Mental Health System”

                                    AstraZeneca Pharmaceuticals

                        

 

2004-2005                   Deanna Kelly (PI: 10%)

                                    “Racial Differences in Clinical Variables, Treatment and Response to Clozapine in Clinical Trials vs. Real-World Treatment Settings”

                                    NIMH P60 grant pilot project

                        

 

2005-2012                   Deanna Kelly (PI: 30%)

                                    Residential Research Support Services        

                                    NIDA N01-DA-5-9909

 

  

2006-2009                   Deanna Kelly (Co-Investigator: 15%)  PI: R. Buchanan

                                      “The Effects of the Cannabinoid-1 Receptor Antagonist, Rimonabant on Weight and Metabolic Risk Factors in People with Schizophrenia”

                                    NIMH 1 R34 MH077839

                      

 

2006-2008                   Deanna Kelly (Coinvestigator no effort) PI:  J.C. Shim

                                    “Varenicline for Neurocognition in Schizophrenia”

                                    Stanley Medical Research Institute

                                   

 

2006-2010                   Deanna Kelly (Co-PI: 10%) PI: R. Buchanan

                                    “Rasagiline in the treatment of persistent negative symptoms in schizophrenia”

                                    Stanley Medical Research Institute (05T-705) with a 1 year extension

                                    

 

2007-2009                   Deanna Kelly (PI: 25%)

                                     “Comorbid Substance Abuse & Long-Term Health Outcomes in Schizophrenia”

                                    NIMH R03 MH076985

                                    

 

2007-2009                   Deanna Kelly (Co-Investigator: 3%) PI: J. Kreyenbuhl

                                    “Schizophrenia PORT Treatment Recommendations Update 2008”

                                    NIMH R13 MH080593

                        

 

2007-2008                   Deanna Kelly (Site Investigator: 1%) PI: Anil Malhotra

                                    “Agranulocytosis Associated Clozapine”

                                    Feinstein Institute Subaward from National Institutes of Health (NIH)

                                   

 

2008-2013                   Deanna Kelly (Co-Investigator: 15%) PI: W. Carpenter

                                    “Center for Intervention Development and Applied Research (CIDAR).

                                       Oxytocin And Galantamine For Negative Symptoms And Cognition In Schizophrenia”

                                       NIMH P50 MH082999

                                    

 

2010-2012                    Deanna Kelly (Site PI: 1%) PI: Jeffrey Lieberman

                                     “Clozapine Incuded Agranulocytosis Consortium (CIAC)”

                                     Subaward on NIMH funded multisite study

                                   

 

2011-2013                    Deanna Kelly (Co-PI/mentor: 1%) PI:  K. Warren

                                    “Effects of Intranasal Oxytocin on Satiety Signaling in People with

                                    Schizophrenia”

                                    NARSAD Young Investigator Award (Grant #17699)

                                    

 

2011-2014                   Deanna Kelly (PI: 15%)

                                    “Adjunctive Minocycline in Clozapine Treatment Patients for Psychosis and

                                    Cognition”

                                    NIMH 1R21MH091184-01A1

                                    

 

2012-2014                   Deanna Kelly (Mentor – no salary support) Julie Markham (PI)                  

                                    Early Life Stress and Schizophrenia-Associated Phenotypes in Animal Models”

                                    Brain & Behavior Research Foundation’s NARSAD Young Investigator Award

 

 

2013 – 2014                Deanna Kelly (PI) (Multiple PI with Reza Ghodssi of UMCP)                        

                                    “Biosensor Device for Clozapine Treatment Monitoring in Schizophrenia”

                                    TEDCO Maryland Innovation Initiative Phase I 

                                   

 

2004-2017                   Carpenter, William; Rowland, Laura (MPIs) Role: Mentor 1%  (no salary support)                                                                                                                                                                         Multidisciplinary Schizophrenia Research Training (T32)

                                    NIH #: 5 T32 MH067533-12

                                    

 

2014 – 2015                Deanna Kelly (Mentor – no salary support) Kate Nugent (PI)          

                                    “Sex-Specific Outcomes after First Episode Psychosis: Relationship to Psychological versus Social Stress Response”

                                    Brain & Behavior Research Foundation’s NARSAD Young Investigator Award                                           

                                    

 

2010-2015                   Deanna Kelly (Co-Investigator and Site PI for trial: 2%)  PI: J.B. Wang

                                    “Development of I-THP as New Medication for Drug Addiction (DP1)”

                                    NIDA X02 1DP1DA031401

                                               

               

 

2011-2016                   Deanna Kelly (PI: 8%)

                                    “Adjunct Aripiprazole for Symptomatic Hyperprolactinemia in Female

                                    Schizophrenia”

                                    NIH 1R01MH09007-01A1

                                    

 

07/01/13 – 6/30/16      Deanna Kelly (Co-Investigator 2%) Buchanan, Robert (PI)

                                    “Oxytocin and Social Skills/Cognitive Behavioral Training in Schizophrenia”

                                    NIMH 1R34MH100362-01 0.60 calendar months

                                   

09/01/15 - 08/31/16     Kelly, Deanna (Co-Investigator: 10%) Himelhoch, Seth (PI)

                                    Optimizing Smoking Cessation Treatments in Smokers Living with HIV/AIDS

                                    1R56HL128148-01A128148-01

                                  .

 

12/01/14 - 11/30/16     Kelly, Deanna, (Co-Investigator, 1%); Hahn, Britta (PI)

                                    “Effects of Nicotine on Dependence-Related Associative Learning Processes”     NIDA 1R03 DA037509-01A1      

                                   

2016-2017                   Buchanan, Robert (PI) Role: (Co-Investigator)

                                    Chair’s Research Seed Funding Award, 

                                    Schizophrenia and the Gut Microbiome

 

6/01/12-11/30/16         Kelly, Deanna (Co-Investigator: 1%) Buchanan, Robert (PI)

                                    Anti-Inflammatory Combination Therapy for the Treatment of Schizophrenia

                                    The Stanley Medical Research Institute Grant # 11T-002    

                                   

 

07/01/13 – 06/30/17    Deanna Kelly (PI 5%)  (Multiple PI with William Eaton of JHU)

                                    “Development for RCT of Gluten Free Diet in Gliadin-Positive Schizophrenia”

                                    NIH 1R34MH100776-01 (Subaward with JHU)

        

 

03/24/16                      Kelly, Deanna (PI)

                                    Supplemental Funding from SMRI Grant #13-007 for entering harmonized and standardized data into the National Database for Clinical Trials related to                                                    mental illness (NDCT)

                                    

 

07/02/16-06/30/17       Kelly, Deanna (PI)

                                    Administrative Supplement

                                    “Biomarker and Safety Study of Clozapine in Benign Ethnic Neutropenia” 

                                      3R01MH102215-02S1                

 

 

4/2016- 3/2017            Kelly, Deanna (PI) 1%

                                    A Phase O Study to Assess Prolactin and Testosterone Levels and Associated Symptoms in Subjects with Schizophrenia

                                    XOMA, LLC

                                    

 

In the News

Media Links and Interviews

  1.   Kelly DL, Conley RR, Love RC. The emerging dilemma: affordable quality care for  schizophrenia. Use of new antipsychotics. Medicaid Update 2002;17(2),             

        www.health.state.ny.us/nysdoh/mancare/omm/2002/feb2002.htm#care.

  2.   McCausland C. Real world training for the next generation: residents. Capsule: University of Maryland School of Pharmacy Magazine. Summer 2010.

  3.   Warren KW, Kelly DL. Brief Psychotic Disorder. British Medical Journal Online 2011-present. https://online.epocrates.com/u/29111118/Brief+psychotic+disorder.

  4.   Worchester S. Oxytocin May Aid Schizophrenia Patients.  Clinical Psychiatry News 2012; 40(8),  www.clinicalpsychiatrynews.com.

  5.   Arehart-Treichel J. Will Antibiotic Fulfull Its Psychosis-Fighting Promise?  Psychiatric News 2012; 47(15), www.pschnews.org

  6.     Arehart-Treichel J. Metformin May Help Combat Antipsychotic-Induced Weight Gain. Psychiatry Online Clinical and Research News 2014;       

       http://psychnews.psychiatryonline.org/newsarticle.aspx?articleid=1866046

 7.    University of Maryland Department of Psychiatry Video at the American Psychiatric Association Meeting 2014 https://vimeo.com/93338481.

 8.   Velasquez-Manoff M. Can Celiac Disease Affect the Brain? New York Times October 11, 1014. http://nyti.ms/1srryi3

 9.    Moran M. Clozapine Monotherapy More Cost-Effective than Antipsychotic Polypharmacy, Study Shows. Psychiatric News October 28, 2014   

       http://psychnews.psychiatryonline.org/doi/10.1176/appi.pn.2014.11b10

 10. Moran M. Why won’t clinicians use clozapine despite proven superiority? Psychiatric News 2015;50(17), www.psychnews.org.

 11. Harrison P. Oxytocin Shows no Effect in Schizophrenia. Medscape Multispeciality Medical News. September 2, 2015 http://www.medscape.com/viewarticle/850411

12. Science Daily. January 18, 2017. Changes in blood-brain barrier, intestinal permeability found in individuals with autism. 

        https://www.sciencedaily.com/releases/2017/01/170118145937.htm

13.  Phys Org. February 9, 2017. Technique to measure oxidative stress in blood samples offers potential aid in schizophrenia diagnosis.  https://phys.org/news/2017-02-technique-     

        oxidative-stress-blood-samples.html

14.  University of Maryland News. UMD Researchers Make Strides in Schizophrenia Diagnosis Research. http://eng.umd.edu/news/story/umd-researchers-make-strides-in-schizophrenia-

       diagnosis-research

15.  Moran M.  Aripiprazole may reduce some side effects of antipsychotics in women.  Psychiatric News.  April 21, 2017.          http://psychnews.psychiatryonline.org/doi/full/10.1176/appi.pn.2017.pp4b2

16. Psychiatric News Alert.  White paper offers recommendations for expanding clozapine use. http://alert.psychnews.org/2017/04/white-paper-offers-recommendations-for.html

 

 

 

 

 

Community Service

Administrative Services

Institutional Services   

2003-2011                   Schizophrenia Patient Outcomes Research Team (PORT)             

Monthly literature searches and database entry, assisted with grant writing, assisted with thought leader meeting, wrote 5 recommendations, assisted with manuscript

2004-2008                     University of Maryland Mental Health Disparities Steering Committee

Committee member representing MPRC, wrote 2 pilot grants and authored two publications, organized disparities speakers and symposia, assisted in other projects, education and outreach

2006-present               T32 MPRC Fellowship Committee

Review and interview fellowship candidates, meet regularly to review progress, assist with grant writing and fellowship program

2007-present               Chair, Junior Faculty Mentoring Committee

Developed formal mentoring program and documents including program description, roadmap, mentorship materials, organize annual mentorship meetings and Department of Psychiatry mentorship programmed modeled after this program

2008-2009                   Acting Chief and Director of the Treatment Research Program, (MPRC),                                                  UMSOM

2008-present               Vice Chair, Department of Health and Mental Hygiene Institutional Review Board. Participate in monthly IRB reviews and meetings and function as Chair in her absence.

2008                           Successfully negotiated a smoking exemption and associated policies and procedures with Spring Grove Hospital to permit smoking in designated areas of MPRC for continued studies in dual diagnosis research

2008-2012                   PI/PO NIDA Research Contract Committee Chair

Developed and maintained infrastructure and oversight of multimillion dollar contract. Committee meets twice monthly to discuss protocol progress, regulatory issues, budgets and personnel on 30 protocols

2009-present               Chief and Director of the Treatment Research Program, MPRC, UMSOM. Administratively coordinate inpatient research program with approximately 13 research staff and 9 clinical staff.

2009-present               Successfully initiated and negotiated the MOU, approval and opening of the 

                                    Brief Stay Unit, a unit at MPRC dedicated to short overnight stays for clinical

                                    Research.

2009                              Department of Psychiatry 60th Anniversary Gala Committee

                                    MPRC liaison monthly meetings for 6 months

2009-present               Administratively direct the Treatment Research Program. This program consists of a 24 bed inpatient program, 13 clinical staff and 12 research staff

2010-present               Co-Direct the Antipsychotic Pharmacy Review Program for the State of Maryland Department of Health and Mental Hygiene and the Medicaid pharmacy program.

2010-2012                   UMSOM Multidisciplinary Advisory Committee (MAC) for K12 Training Awards. Monthly meeting to discuss and review awardees in the SOM

2010                            Successfully negotiated a MOU between the University of Maryland IRB and the Department of Health and Mental Hygiene IRB for reliance on protocols

2011                            Organizer of 2011 speakers for series entitled, “Biological Psychiatry of Immune and Inflammatory Mechanisms of Schizophrenia.”  Organized and invited outside speakers for the series.

2011-present               Director, Brief Stay Unit, MPRC, UMSOM. Developed and direct 3 bedroom short stay unit for early phase studies.

2011-present               UMB Department of Psychiatry Appointment, Promotions and Tenure (APT) Committee

2012-present               Administrative support including infrastructure, space and allocate personnel to the Maryland Peer to Peer Antipsychotic Review Project.  Oversee space and infrastructure issues related to the pharmacy department of 6 clinical pharmacists.

2012-present               Building Interdisciplinary Research Careers in Women’s Health (BIRCWH) Internal Advisory Committee member, UMB

2013-2016                   Videoconferencing committee, Department of Psychiatry

2013-present               Coordinator, Psychiatry Resident Electives at MPRC

2013-present               Silvio O. Conte Summer Scholar Selection and Review Committee

2015-present               Maryland Brain Collection Steering Committee

2016-present               Full faculty member to UMSOM council


National and International Service

2002                            NIMH Pharmacoeconomics Advisory Board      

2004-2006                   Treasurer and Board of Directors, College of Psychiatric and Neurologic

                                    Pharmacists (CPNP)

2004-2009                   Department of VA Mental Health and Behavioral Sciences Review

                                    Committee for National VA merit grants

2004                            Elected Treasurer and Board Member in the College of Psychiatric and      Neurologic Pharmacists (CPNP)

2005                                      Canadian Institutes of Health Research grant reviewer

2005-2008                   Member, Membership Committee, College of Psychiatric and Neurologic

                                    Pharmacists (CPNP)

2005-2008                   Member, Finance Committee, College of Psychiatric and Neurologic

                                    Pharmacists (CPNP)

2005-2008                   Member, Web Task Force, College of Psychiatric and Neurologic

                                    Pharmacists (CPNP)

2005-present               Editorial Board Member, Schizophrenia Bulletin

2006                            Health Care Efficiency Research Programme (Netherlands) grant reviewer

2006                                      Thrasher Research Fund grant reviewer

2006                            Textbook reviewer for Burger’s Sixth Edition Medicinal Chemistry and Drug

                                    Discovery

2006-2009                   Member, Communications Committee, College of Psychiatric and

                                    Neurologic Pharmacists (CPNP)

2007                            Member, Awards Committee, College of Psychiatric and Neurologic

                                    Pharmacists (CPNP)

2007                                      Mission trip to Ecuador, developed library at Spanish speaking school

2011-2017                   Program Committee, CPNP

2011-2015                   Grant Reviewer, United Kingdom, National Institute for the Health Research and Policy Research Programme

2011-2013                   NIH Special Emphasis Panel/Scientific Review Group ZRG1 EMNR-R (55)

2012-2013                   NIDA IRP Independent Monitoring Board

2013                            NIH workshop (NIMH, NIDA, NCI) for Smoking Cessation in Schizophrenia

2013-2014                   Program Chair, CPNP Annual Meeting, 2014

2013-2017                   Data Safety Monitoring Board, NIH, Intramural Research Program

2016-present               Government Affairs committee, CPNP

2016-present               National Association of State Mental Health Programs Director (NASMHPD) clozapine white paper task force

2016-presnet               Food and Drug Association (FDA) network of experts

2017                            Substance Abuse and Mental Health Services Administration (SAMHSA) taskforce for Behavioral Health Pharmacist integration in Psychiatry

2017                            Substance Abuse and Mental Health Services Administration (SAMHSA) taskforce for Clozapine Centers of Excellence

 

Local Service

1996-present               Volunteer, Treatment Research Program/Spring Grove Hospital Talent Show and Family Events

2005-present               Maryland NAMI fundraisers, walks, charity events

2005-present               Volunteer, CentralYorkSchool District

2006-present               Community Service projects through LivingWordCommunityChurch

2008-present               Participant and mentor in the Atholton High School Gifted program

2008-2012                   Volunteer, SpringGroveHospital 5K event

2011-2013                   Board Member, Typical Life Corporation, Inc.

2015-present               State of Maryland Behavioral Health Administration Clozapine Task Force

 

Journal Editor and Review

1998-present               American Journal of Psychiatry (2x/yr), BioMed Central (BMC) Psychiatry          (6x/yr), CNS Drugs (1x/yr), Journal of Clinical Psychiatry (4x/yr), Journal of        Clinical Psychopharmacology (1-2x/yr), Journal of Psychiatric Research (1-  2x/yr), Journal of Nervous and Mental Disease (1x/yr), Progress in Neuro-Psychopharmacology and Biological Psychiatry (1-2x/yr), Psychiatric Services (3x/yr), Psychiatry Research (3x/yr), Schizophrenia Research (4x/yr), Schizophrenia Bulletin (4-5x/yr)

1999-2000                   Journal of Post Graduate Medicine, Israeli Journal of Psychiatry, Journal of Child and Adolescent Psychopharmacology

2000-2002                   Acta Pharmacologica Sinica, Indian Journal of Medical Sciences, Journal of Pediatric Nephrology, European Archives of Psychiatry and Clinical Neuroscience

2003-2004                   Advances in Schizophrenia and Clinical Psychiatry, Archives of Medical Research, Expert Review Neurotherapeutics, Journal of Sexual Medicine

2005-2006                   Disease Management and Health Outcomes, Expert Review of Pharmacoeconomics and Outcomes Research, European Psychiatry

2007-2008                   Pharmacopsychiatry, Women & Health

2009                            Journal of Psychopharmacology, Human Psychopharmacology: Clinical and Experimental, Journal of the American Psychiatric Nurses Association

2010                            Acta Psychiatrica Scandinavica, Psychoneuroendocrinology, Archives of General Psychiatry

2011                            Neuropsychopharmacology

2016                            Journal of Forensic Psychiatry and Psychology

 

Editor:

2006-present               Associate Editor, Clinical Schizophrenia and Related Psychosis (40 per year)

2006-present               Editorial Board Member, Clinical Schizophrenia and Related Psychosis

2008-present               Associate Guest Editor, Schizophrenia Bulletin (5 per year)

2009-present               Associate Editor, BMC-Psychiatry (6 per year)

2011-present               Editorial Board Member, Current Psychopharmacology (2 per year)

The Maltz Prize for Innovative & Promising Schizophrenia Research (Video)

The Maltz Prize for Innovative & Promising Schizophrenia Research was awarded to Deanna L. Kelly, Pharm.D., BCPP at the University of Maryland School of Medicine.

Please visit Brain & Behavior Research Foundation to learn more.